Contact Information

Available for logged-in reporters only

Newswise Researchers have identified the first genetic variations linked to race that begin to explain a higher risk of death among some African American and Caucasian patients taking the anti-clotting drug clopidogrel (Plavix) after a heart attack.

These variants increased patients risk of dying in the year following a first heart attack, but they appeared to do so for different reasons depending on race, according to a study at Washington University School of Medicine in St. Louis.

In particular, the team found that two DNA variants common in African Americans were associated with an increased risk of both bleeding and death. In Caucasians, a different variant was linked to additional heart attacks and a higher risk of death.

The research is published June 17 in the American Heart Association journal Circulation: Cardiovascular Genetics.

The variations influence the way people metabolize clopidogrel and can alter its effectiveness. The blood-thinning drug commonly is prescribed after a heart attack to reduce the likelihood of another heart attack or a stroke.

The research is provocative, said the studys first author, cardiologist Sharon Cresci, MD, assistant professor of medicine and of genetics. Knowing about potential genetic differences based on race can help physicians tailor drugs to patients based on their genetic makeup.

Clopidogrel is metabolized in the liver, where it is turned into its active form via a group of enzymes called cytochrome P450, or CYP for short. Although clopidogrel is effective in many patients, earlier studies determined that some people metabolize the drug better than others.

Indeed, in 2010, the Food and Drug Administration added a black box warning to labels of clopidogrel after research that primarily involved Caucasians showed that people with a particular CYP genetic variant metabolized the drug poorly, which reduced the amount of the drug circulating in the blood. These patients had a higher risk of heart attack and stroke.

More here:
Genetic Find Shows Race a Factor in Higher Mortality Risk in Heart Attack Patients on Anti-Clotting Drug

Recommendation and review posted by Bethany Smith

Let #39;s Play The Sims 3 - Perfect Genetics Challenge: Cowgirl and Horse Edition Episode 1
Come join me on my latest journey into the complex world of sims 3 genetics, as I try to get perfect foals and perfect children. Will I succeed in getting perfect genetics in both? Can I keep...

By: GamerGirlsNetwork

Excerpt from:
Let's Play The Sims 3 - Perfect Genetics Challenge: Cowgirl and Horse Edition Episode 1 - Video

Recommendation and review posted by Bethany Smith

Jon Rappoport on Genetics Transhumanism
Jon Rappoport on Genetics Transhumanism (FAIR USE) Jon Rappoport has worked as a free-lance investigative reporter for over 30 years.He has written articles on politics, health, media, culture...

By: localmcmedianed

More here:
Jon Rappoport on Genetics & Transhumanism - Video

Recommendation and review posted by Bethany Smith

Let #39;s Play The Sims 3 - Perfect Genetics Challenge: Cowgirl and Horse Edition Episode 2
Come join me on my latest journey into the complex world of sims 3 genetics, as I try to get perfect foals and perfect children. Will I succeed in getting perfect genetics in both? Can I keep...

By: GamerGirlsNetwork

See the rest here:
Let's Play The Sims 3 - Perfect Genetics Challenge: Cowgirl and Horse Edition Episode 2 - Video

Recommendation and review posted by Bethany Smith

Let #39;s Play The Sims 3 - Perfect Genetics Challenge: Cowgirl and Horse Edition Episode 4
Come join me on my latest journey into the complex world of sims 3 genetics, as I try to get perfect foals and perfect children. Will I succeed in getting perfect genetics in both? Can I keep...

By: GamerGirlsNetwork

View post:
Let's Play The Sims 3 - Perfect Genetics Challenge: Cowgirl and Horse Edition Episode 4 - Video

Recommendation and review posted by Bethany Smith

Let #39;s Play The Sims 3 - Perfect Genetics Challenge: Cowgirl and Horse Edition Episode 5
Come join me on my latest journey into the complex world of sims 3 genetics, as I try to get perfect foals and perfect children. Will I succeed in getting perfect genetics in both? Can I keep...

By: GamerGirlsNetwork

Link:
Let's Play The Sims 3 - Perfect Genetics Challenge: Cowgirl and Horse Edition Episode 5 - Video

Recommendation and review posted by Bethany Smith

Contact Information

Available for logged-in reporters only

Newswise BETHESDA, MD Nearly 900 scientists from 27 countries will attend the 11th International Conference on Zebrafish Development and Genetics organized by the Genetics Society of America (GSA), June 2428, 2014, in Madison, Wisconsin. The conference will feature 600 presentations of cutting-edge research results on topics including embryonic and adult development, functional genomics, regenerative medicine, chemical biology, emerging technologies, evolution, and cancer as well as cardiovascular, digestive, and infectious diseases. In addition to the scientific programming, the GSA has organized several sessions designed to provide career development for the 60% of student and postdoctoral attendees; this includes a daylong pre-conference Trainee Bootcamp that will provide guidance on obtaining research funding and pursuing careers within and beyond academia.

One of the highlights of the meeting will be the Chi-Bin Chien Award lecture on Thursday, June 26th, which is presented by an outstanding graduate student, postdoctoral trainee, or recently appointed faculty member. This award honors zebrafish researcher Dr. Chi-Bin Chien (19652011) and his enthusiasm for the discussion of scientific ideas and the synergistic ideas that arise from interactions and open conversation among researchers, his efforts to mentor and support young scientists, and the collaborative and generous spirit with which he contributed to advances in zebrafish research. The 2014 awardee and only the second recipient of this award is postdoc Andrea Pauli, PhD (Harvard University), who will speak about her work on developmental genomics: From genomics to novel gene functions in zebrafish.

The zebrafish (Danio rerio) is a popular model organism for studying vertebrate development and genetics, because it is : 1) well-characterized at the molecular and behavioral levels, 2) practical to work with in a laboratory setting, 3) able to regenerate several of its organs, and 4) large and transparent during embryonic development. Because of its genetic similarity to humans, the zebrafish is also a common model for human disease and toxicity testing. As with other model organisms around which GSA organizes conferences, research using zebrafish has enabled breakthrough discoveries in genetics that have advanced our understanding of fundamental biology and provided valuable insights into human disease. The biennial conference brings together leading laboratories using this important organism, and will showcase some of the latest significant developments in genetics research.

For additional information, please see the conference website at http://www.genetics-gsa.org/zebrafish/2014/.

Media Eligibility:

The 11th International Conference on Zebrafish Development and Genetics is open to media representatives, including those from bona fide print, broadcast, radio, and online venues, and freelance writers on a verifiable assignment from an established news source. Please contact press@genetics-gsa.org for information about complimentary press registration.

* * *

About the Genetics Society of America (GSA) Founded in 1931, the Genetics Society of America (GSA) is the professional scientific society for genetics researchers and educators. The Societys more than 5,000 members worldwide work to deepen our understanding of the living world by advancing the field of genetics, from the molecular to the population level. GSA promotes research and fosters communication through a number of GSA-sponsored conferences including regular meetings that focus on particular model organisms. GSA publishes two peer-reviewed, peer-edited scholarly journals: GENETICS, which has published high quality original research across the breadth of the field since 1916, and G3: Genes|Genomes|Genetics, an open-access journal launched in 2011 to disseminate high quality foundational research in genetics and genomics. The Society also has a deep commitment to education and fostering the next generation of scholars in the field. For more information about GSA, please visit http://www.genetics-gsa.org.

Read the original post:
Zebrafish Research Meeting to Highlight Advances in Genetics and Developmental Biology

Recommendation and review posted by Bethany Smith

(2012-08b) Ron Rothenberg - Inflammation, Hormones, Stem Cells Telomeres
W URL at: https://www.youtube.com/watch?v=h6JOZ6i6MBw Update in Preventive/Regenerative Medicine -- Inflammation, Hormones, Stem Cells and Telomeres- by Ron ...

By: Silicon Valley Health Institute

More here:
(2012-08b) Ron Rothenberg - Inflammation, Hormones, Stem Cells & Telomeres - Video

Recommendation and review posted by Bethany Smith

Knee and shoulder arthritis/torn rotator cuffs 16 months after stem cell therapy by Dr Harry Adelson
Mike discusses his results 16 months after stem cell therapy for his arthritic knees and shoulders and torn rotator cuffs by Dr Harry Adelson at http://www.docerecl...

By: Harry Adelson, N.D.

See the original post:
Knee and shoulder arthritis/torn rotator cuffs 16 months after stem cell therapy by Dr Harry Adelson - Video

Recommendation and review posted by simmons

La Jolla, CA (PRWEB) June 17, 2014

StemGenex, the leading resource for adult adipose stem cell therapy in the US aimed at improving the lives of patients dealing with degenerative diseases, today announced their newest clinical study for Multiple Sclerosis. StemGenex believes that a commitment to the safety and efficacy of stem cell therapy are paramount when providing care to patients with life threatening diseases.

This clinical study is bringing to the field a new, unique type of stem cell therapy that has the possibility of being more effective than other stem cell treatments currently available. Patients who receive stem cell treatment through StemGenex for Multiple Sclerosis will receive StemGenex multiple administration protocol. This consists of four targeted administration methods of the stem cells to deliver the necessary amount of stem cells past the blood brain barrier.

Principal Investigator Dr. Jeremiah McDole, Ph.D. stated, "Currently available drugs for multiple sclerosis do not halt disease progression or aid in the repair of established damage. We strive to provide regenerative medicine applications that address this critical, underlying issue. While patients experience positive clinical outcomes as a result of stem cell treatment, large, rigorously performed studies are desired in order to guide our best efforts for future development. The study we are conducting is designed to provide us with this essential data."

This study is registered through The National Institutes of Health which can be found at http://www.clinicaltrials.gov and is being conducted under IRB approval. According to StemGenex Director of Patient Advocacy, Joe Perricone, It is important patients have access to top-tier stem cell treatment. By providing access to registered clinical studies through The National Institutes of Health, we are providing patients with the ability to choose a stem cell treatment center with the highest standard of care.

Rita Alexander, founder and president of StemGenex, stated, This is the first of many stem cell clinical studies to come and a positive step for the more than 2 million people around the world suffering with Multiple Sclerosis. The average lifetime cost of current standard of care treatment per MS patient is $1.2 million. The human cost of the disease including pain and suffering endured by MS patients, the profound impact on families and the loss of their ability to contribute to society is without question immeasurable. Dr. McDoles research background in neuroimmunology is certainly an asset in our effort to change the course of neurological diseases.

Stem cell treatment studies are currently being offered by StemGenex to patients diagnosed with Multiple Sclerosis and other degenerative neurological diseases. StemGenex takes a unique approach of compassion and empowerment while providing access to the latest stem cell therapies for degenerative neurological diseases including Parkinsons and Alzheimers disease, stroke recovery and others.

To find out more about stem cell therapy, contact StemGenex either by phone at (800) 609-7795 or email Contact(at)stemgenex(dot)com

More here:
StemGenex Announces New Stem Cell Clinical Study for Multiple Sclerosis

Recommendation and review posted by simmons

Contact Information

Available for logged-in reporters only

Newswise LOS ANGELES (June 17, 2014) Stem cell therapy for cardiovascular disease isnt a medical pipe dream its a reality today, although patients need to better understand the complex science behind these experimental treatments, according to the chief of Cardiology for the Cedars-Sinai Heart Institute.

In a 17-minute TEDxGrandForks talk now available on YouTube.com, Timothy D. Henry, MD, known for his innovative work in developing stem cell treatments for advanced heart disease patients, said he understands why so many are confused about the latest scientific findings.

Most people today get our information from sound bites, and the issues surrounding stem cells are too complex to be fully explained in a single catchy phrase, Henry said, adding, We have far too much controversy about stem cells and far too much hype.

Stem cell science has become a political dividing line with many opposing research into stem cells derived from human embryos, Henry said. However, he said, todays leading-edge clinical research focuses on stem cells derived from adults that can be scientifically programmed to become a specialized cell, such as a heart cell or a brain cell, thereby avoiding the ethical questions involved in embryonic research.

Very few of the cells we give actually become muscle or actually become blood vessels, Henry said. What they do is increase growth factors and encourage natural cells in the body to generate new, healthy tissue.

The Cedars-Sinai Heart Institute, directed by Eduardo Marbn, MD, PhD, is a world leader in studying the use of stem cells to regenerate heart muscle in patients who have had heart attacks. In 2009, Cedars-Sinai physicians conducted the first infusion of stem cells into heart attack patients, using stem cells grown from the patients own heart tissue. The resulting study, published in February 2012 in The Lancet, showed that patients who underwent the stem cell procedure experienced a significant reduction in the size of the scar left behind by a heart attack. Patients also experienced a sizable increase in healthy heart muscle following the experimental stem cell treatments.

Currently, Henry is co-directing a new stem cell study with Raj Makkar, MD, director of Interventional Cardiology. The national trial, called ALLSTAR, uses heart cells from unrelated donors in an effort to reverse lasting tissue damage after a heart attack.

During his talk, Henry also expressed concern for patients who might be taken advantage of by unscrupulous clinics outside of the United States that offer stem cell cures for everything from neurological diseases to baldness. Patients also need to understand that stem cell science has a long way to go before regenerative medicine treatments are widely available.

See the original post here:
Stem Cell Expert Explains How Experimental Regenerative Medicine Therapies Can Regrow Damaged Heart Muscle

Recommendation and review posted by simmons

When patients have to undergo a bone marrow transplant, the procedure weakens their immune system. Viruses that are usually kept in check in a healthy immune system may then cause potentially fatal infections. Scientists at Technische Universitt Mnchen (TUM), together with colleagues from Frankfurt, Wrzburg and Gttingen, have now developed a method which could offer patients conservative protection against such infections after a transplant. The method has already been used to treat several patients successfully.

The cells of the human immune system are created from special stem cells in the bone marrow. In diseases affecting the bone marrow, such as leukemia, the degenerate cells must be destroyed using radiation or chemotherapy. Subsequently, the hematopoietic system has to be replaced with stem cells from the blood of a healthy donor. Because of the resulting temporary weakening of the immune system, patients are more exposed to viruses that would normally be warded off.

The cytomegalovirus (CMV), which can cause serious damage to lungs or liver in persons with a weakened defense, poses a major clinical problem. In healthy human beings, a CMV infection will usually not produce any symptoms, since the virus is kept at bay by specific immune cells. In their work, the scientists were able to demonstrate that the transfer of just a few specific immune cells is sufficient to protect the recipient with the weakened immune system against infections. To do this, they used T cells that can recognize and kill specific pathogens.

Tested in an animal model

Dr. Christian Stemberger, first author of the study, and his colleagues, first isolated T cells from the blood of healthy donor mice. These immune cells were directed against molecular elements of a bacterial species which normally causes severe infections in animals. The T cells were then transferred to recipient mice that, due to a genetic modification, could no longer produce immune cells of their own -- similarly to patients suffering from leukemia.

Following the T cell transfer, the researchers infected the treated recipient mice with the bacteria. The results showed that the animals now have effective immune protection against the pathogens, preventing them from becoming ill. "The most astonishing result was that the offspring cells of just one transferred donor cell were enough to completely protect the animals," Christian Stemberger explains.

Successfully used in patients

Finally, the scientists used virus-specific T cells to treat two critically ill patients. Due to a congenital immunodeficiency and leukemia, respectively, stem cell transplants had to be performed on the two patients. Weakened by the procedure, both patients developed CMV infections.

Using a new method, the scientists therefore isolated T cells specifically programmed to target the CMV virus from the blood of the donor and transferred small numbers of these cells to the patients. After only a few weeks, the virus-specific cells proliferated. At the same time, the number of viruses in the blood dropped. "It is a great advantage that even just a few cells can provide protection. This means that the cells can be used for preventive treatment in low doses that are gentler on the organism," Dr. Michael Neuenhahn, last author of the study, explains.

The potential of the identified T cells will now be examined in a clinical study. In addition to an innovative method for cell purification, scientists also have at their disposal a new TUM facility for the sterile manufacture of cell products. In TUMCells, cells can be produced in highly-pure conditions, in so-called clean rooms. In the future, the scientists want to use recent results and TUMCells to develop innovative cell therapies.

Continue reading here:
Promising T cell therapy to protect from infections after transplant

Recommendation and review posted by Bethany Smith

June 17, 2014

Image Caption: ImStem Biotechnologys Xiaofang Wang, seated, and Ren-He Xu. Credit: Tina Encarnacion/UConn

University of Connecticut

Scientists in the University of Connecticuts Technology Incubation Program have identified a novel approach to treating multiple sclerosis (MS) using human embryonic stem cells, offering a promising new therapy for more than 2.3 million people suffering from the debilitating disease.

The researchers demonstrated that the embryonic stem cell therapy significantly reduced MS disease severity in animal models, and offered better treatment results than stem cells derived from human adult bone marrow.

The study was led by ImStem Biotechnology Inc. of Farmington, Conn., in conjunction with UConn Health Professor Joel Pachter, Assistant Professor Stephen Crocker, and Advanced Cell Technology (ACT) Inc. of Massachusetts. ImStem was founded in 2012 by UConn doctors Xiaofang Wang and Ren-He Xu, along with Yale University doctor Xinghua Pan and investor Michael Men.

The cutting-edge work by ImStem, our first spinoff company, demonstrates the success of Connecticuts Stem Cell and Regenerative Medicine funding program in moving stem cells from bench to bedside, says Professor Marc Lalande, director of the UConns Stem Cell Institute.

The research was supported by a $1.13 million group grant from the state of Connecticuts Stem Cell Research Program that was awarded to ImStem and Professor Pachters lab.

Connecticuts investment in stem cells, especially human embryonic stem cells, continues to position our state as a leader in biomedical research, says Gov. Dannel P. Malloy. This new study moves us one step closer to a stem cell-based clinical product that could improve peoples lives.

The researchers compared eight lines of adult bone marrow stem cells to four lines of human embryonic stem cells. All of the bone marrow-related stem cells expressed high levels of a protein molecule called a cytokine that stimulates autoimmunity and can worsen the disease. All of the human embryonic stem cell-related lines expressed little of the inflammatory cytokine.

The rest is here:
Embryonic Stem Cells Offer Promising Treatment For Multiple Sclerosis

Recommendation and review posted by Bethany Smith

Global Stem Cell Therapy Industry Pipeline Analysis 2020
Stem Cell Therapy Industry @ http://bit.ly/1qkbHjQ.

By: Ashley Harvey

Here is the original post:
Global Stem Cell Therapy Industry Pipeline Analysis 2020 - Video

Recommendation and review posted by Bethany Smith

Stem Cell Therapy in South Korea
When traditional treatments fail, Stem Cell Therapy in South Korea offers hope to worldwide patients.

By: placidways

Originally posted here:
Stem Cell Therapy in South Korea - Video

Recommendation and review posted by Bethany Smith

Patient Testimonial: Stem cell therapy for Multiple Sclerosis
http://www.placidway.com/profile/1617/ - Stem cell therapy in Switzerland was effective for 44 year old patient who had multiple sclerosis. He explains how the side effects started to diminish...

By: placidways

Originally posted here:
Patient Testimonial: Stem cell therapy for Multiple Sclerosis - Video

Recommendation and review posted by Bethany Smith

Lumbar disc pain one year after stem cell therapy by Dr Harry Adelson
Lisa describes her outcome one year after having bone marrow stem cells injected into her degenerated and dehydrated lumbar discs by Dr Harry Adelson http://www.docereclinics.com.

By: Harry Adelson, N.D.

More here:
Lumbar disc pain one year after stem cell therapy by Dr Harry Adelson - Video

Recommendation and review posted by Bethany Smith

Australian innovation: Bio-Living Cell Therapy
Experience full rejuvenation for you health, skin and hair with this breakthrough technology! Bio-Living Cell therapy is a brilliant Australian innovation of...

By: Victory Bio-Living Cell Therapy

More here:
Australian innovation: Bio-Living Cell Therapy - Video

Recommendation and review posted by Bethany Smith

Scientists have identified gene mutations that reduce levels of fatty triglycerides in some people and cut their heart attack risks, potentially paving the way for new types of drugs.

For years, drugmakers focused on adjusting cholesterol levels to help people hold off heart problems. Now, a new pharmaceutical strategy may be forming based on two studies reported in the New England Journal of Medicine. The research identified mutations in the APOC3 gene that decreased heart disease risk in some people by about 40 percent.

Triglycerides are a form of fat created from excess calories the body doesnt immediately use after eating. They gather in the bloodstream as a helpful way to store energy. Having levels that are too high, however, has long been linked to heart disease, though scientists have never definitively determined whether it was a cause or a signal.

The results of our study highlight the potential usefulness of naturally occurring loss-of-function mutations in guiding the selection of therapeutic targets, the researchers, led by Sekar Kathiresan, a cardiologist at Massachusetts General Hospital in Boston, said in one of the reports.

When working properly, APOC3 creates a protein that slows down removal of triglycerides from the blood to make sure the body has energy when it needs it. The mutations may allow the fat to be more quickly eliminated, the studies suggest. Creating drugs that mimic this action may be a natural next step, the scientists suggested.

Despite advances that range from drugs that control bad cholesterol, such as the Pfizer Inc. (PFE) statin Lipitor, and devices that help keep blood flowing, such as stents, heart disease remains the leading cause of death in the U.S., according to the Atlanta-based Centers for Disease Control and Prevention. It kills about 600,000 peopleyearly.

Kathiresans team sequenced genes in more than 3,734 people to identify the APOC3 mutations. They then expanded the genetic search to more than 100,000 people to determine a 40 percent lower risk profile among those who carried the variants.

A second study in more than 75,000 people, led by Anne Tybjaerg-Hansen of Copenhagen University Hospital, determined that people with the variants have a 44 percent drop in triglycerides. Their chance of having ischemic heart disease was 36 percent less than the general population, Tybjaerg-Hansen reported.

To contact the reporter on this story: Reg Gale in New York at rgale5@bloomberg.net

To contact the editors responsible for this story: Reg Gale at rgale5@bloomberg.net Suresh Seshadri

Read the original:
Gene Mutations That Lower Heart Risks May Spur New Drugs

Recommendation and review posted by Bethany Smith

The identification of the gene responsible for IPN resistance in salmon enables a great accuracy in the selection of broodstock, ensuring the offspring to be resistant to IPN.

This gene is found to have two mutations that prevent the IPN virus from infecting salmon cells.

On 10-12 June 2014 the second international conference on integrated salmon biology was held in Vancouver, Canada.

This conference marked the completion of the salmon genome project. This work started in 2010 as a collaborative project between academia, industry and government funding agencies in Chile, Canada and Norway.

It is expected that the reference genome for salmon will provide important information of great benefit to the salmon farming in the future.

One example of the use of genetic information that has already brought significant improvements for farmed fish are genetic markers for resistance to infectious pancreatic necrosis (IPN) in salmon.

At the conference, seniorscientist Thomas Moen from AquaGen presentedthe work doneto discover the actual gene and reveal the mechanism behind IPN resistance in salmon.

IPN is a very common viral disease, and is one that has been responsible for significant losses in salmon farming.

The disease has proven to be very difficult to control by vaccination or other preventive or loss-reduction measures adopted over the years.

By the late 90s it had been documented that there was a significant genetic variation in salmon susceptibility to IPN.

Read the original here:
IPN gene and resistance mechanism identified

Recommendation and review posted by Bethany Smith

Contact Information

Available for logged-in reporters only

Newswise BETHESDA, MD June 17, 2014 Sex is everywhere in nature. Whether its a male bird singing to mark his territory or a tiny yeast cell secreting chemicals to attract the opposite mating type, sex has profoundly shaped the appearance, behavior and evolution of many organisms. The genetic and evolutionary forces underlying sex differences and sex determination are crucial for understanding much of the natural world, including human biology.

In recognition of the importance of these topics, the Genetics Society of America journalsGENETICSandG3: Genes|Genomes|Genetics announce an ongoing collection of research articles that discuss various elements relating to the genetics of sex. The first group of articles in the collection is published today in a special section of the June issues of both journals, accompanied by a commentary article.

By creating a special focus on the genetics of sex and bringing together related articles in one collection, the journals hope to encourage cross-fertilization of ideas between researchers working on related problems from different angles.

The inaugural group features research examining the evolutionary loss of Y-chromosomes, sexually antagonistic selection, switching between sexual and asexual reproduction in certain fungi, mechanisms preventing self-fertilization in plants, and the genesis of sex cells in nematodes and maize. The journals today also publish a commentary which illustrates the connections between sometimes-seemingly disparate topics related to sex-specific biology.

The fundamental genetic differences between the sexes and how they arise continue to fascinate biologists, says Michelle Arbeitman, biologist at Florida State University and one of the editors of the new collection. We foresee these first papers as just the start of the conversation, illuminating discoveries both broad and deep.

The collection includes research from Stanford University, University of Texas at Arlington, the National Evolutionary Synthesis Center, University of Texas, Universit Laval, University of California, Davis and University of Modena and Reggio Emilia.

The full collection can be found at: http://www.genetics.org/site/misc/GeneticsOfSex.xhtml

CITATIONS: M. Arbeitman, A. Kopp, M. Siegal and M. Van Doren. The Genetics of Sex: Exploring Differences. GENETICS June 2014 197:527-529; doi: 10.1534/genetics.114.165456

See the rest here:
Genetics of Sex - Beyond Just Birds and Bees

Recommendation and review posted by Bethany Smith

Isis Pharmaceuticals Inc. (ISIS), a maker of gene therapy treatments, may seek to expand use of an experimental drug targeting triglycerides to fight heart disease, a move an analyst says could add $2 billion in sales.

The drug targets the APOC3 gene and is now aimed solely at a rare disease thats linked to diabetes and pancreatitis and affects about 5,000 people. Two studies this week, however, have also tied the gene to lower risk of heart disease, an illness that kills 600,000 people yearly, a much larger target.

The research, done independently of Isis, was highlighted in the New England Journal of Medicine. It may open a new window of opportunity for Isis once the drug, called ISIS-APOCIIIRx and heading to final testing, is approved and may spark interest from potential acquirers, analysts said.

Were weighing how we want to take full advantage of this breakthrough, and as we do that we have to consider the potential broader development of the follow on product, Isis Chief Executive Officer Stanley Crooke said by telephone. We have a great deal of licensing interest for this drug.

In the New England Journal of Medicine studies, mutations in the APOC3 gene decreased the risk of a heart attack by about 40 percent. Adding value to the current drug could open the company up to a takeover bid, said Joshua Schimmer, a Piper Jaffray & Co. analyst in New York.

The Carlsbad, California-based company has a super deep pipeline, and none of it is adequately reflected in the stock price, Schimmer said in a telephone interview. At this valuation, it would be ripe for a hostile event.

Isis, founded by by Crooke in 1989, has grown to a $4.09 billion market capitalization and a pipeline of 32 products. Today the stock rose 3.2 percent to $34.82 at 4 p.m. New York time. It has dropped 41 percent since reaching a record high of $59 on February 21, compared with a 6.8 percent drop in the Nasdaq Biotechnology Index.

Normally, the APOC3 gene works by creating a protein that slows down removal of triglycerides from the blood to make sure the body has energy when it needs it. The mutations may allow them to be more quickly eliminated, the studies suggested.

Triglycerides are a form of fat created from excess calories the body doesnt immediately use after eating. They gather in the bloodstream as a helpful way to store energy. Having levels that are too high, however, has long been linked to heart disease, though scientists have never definitively determined whether it was a cause or a signal.

The drugs current path for FCS, meanwhile could generate as much as $2 billion in sales, Piper Jaffrays Schimmer. If Isis expands the drugs use to those at high risk of heart disease, it could double sales to $4 billion, he said. Heart disease is the leading cause of death in the U.S., according to the Centers for Disease Control and Prevention.

Follow this link:
Isis Could Get a $2 Billion Gain From Heart Attack Trials

Recommendation and review posted by Bethany Smith

C5 c6 spinal cord injury
Walking again after 5 months of sci E.

By: Sem Khan

View post:
C5 c6 spinal cord injury - Video

Recommendation and review posted by sam

Fathers Day Draw 2014 Spinal Cord Injury Foundation NL
FATHER #39;S DAY DRAW 2014 WINNING NUMBERS 1ST PRIZE $10000 TICKET # 29729 2ND PRIZE $3000 TICKET # 37673 3RD PRIZE $2000 TICKET # 7615 2 PRIZES OF $500 ...

By: Spinal Cord Injury NL

See the original post here:
Fathers Day Draw 2014 Spinal Cord Injury Foundation NL - Video

Recommendation and review posted by sam

Obesity Weight (Stem Cell Therapy)
The subject matter of this video Obesity Weight.

By: Mohammad Sadique

See the rest here:
Obesity & Weight (Stem Cell Therapy) - Video

Recommendation and review posted by simmons